SCHEMBL4965644

SCHEMBL4965644

CC(=O)c1cccc(NC(=O)OC2CCCCC2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
CYP1A2 P05177 3/20 0.68
CYP3A4 P08684 2/20 0.68
MAPT P10636 2/20 0.68
FAAH O00519 1/20 0.67
MGLL Q99685 1/20 0.67
ALDH1A1 P00352 2/20 0.64
PKM P14618 2/20 0.61
ALOX15 P16050 1/20 0.61
NPC1 O15118 3/20 0.59
LMNA P02545 2/20 0.59
TDP1 Q9NUW8 1/20 0.58
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
RAB9A P51151 2/20 0.54
HPGD P15428 2/20 0.53
TSHR P16473 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698168 0.86 FAAH (0.64) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL10089336 0.84 MEN1 (0.70) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL698540 0.83 FAAH (0.60) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL10192096 0.83 MEN1 (0.67) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL30445128 0.82 RAB9A (0.58) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL30444625 0.81 FAAH (0.60) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL1147281 0.81 FAAH (0.75) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL4274165 0.81 MGLL (1.00) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL29633028 0.81 MGLL (1.00) MEN1KMT2ACYP1A2CYP3A4MAPT
SCHEMBL2576912 0.81 FAAH (0.76) MEN1KMT2ACYP1A2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101351495-A fatty acid amide hydrolase inhibitors ORGANON NV (NL) 2009-01-21 CN disclosed
EP-1969051-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2008-09-17 EP disclosed
WO-2008024139-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2008-02-28 WO disclosed
WO-2007079180-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2007-07-12 WO disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 MEN1 4781/4885KMT2A 2252/4885CYP1A2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.